Researchers have found a way to see synthetic nanostructures and molecules using a new type of super-resolution optical microscopy that does not require fluorescent dyes, representing a practical tool for biomedical and nanotechnology research.
Despite advances that have been made in sunscreen technology and growing public awareness of the need for sunscreen, recent data have found that the average U.S. lifetime risk of invasive melanoma has increased from 1 in 600 in 1960 to 1 in 50 in 2008.
Cells ingest proteins and engulf bacteria by a gymnastic, shape-shifting process called endocytosis. New research reveals, on the real-life scale of nanometers, how individual molecules work together during a single act of endocytosis.
Pfizer Inc.'s first-quarter net income rose 53% despite growing generic drug competition as the drugmaker benefited from a gain related to a joint venture with China. But the company's results still fell short of Wall Street's expectations, and Pfizer lowered its 2013 profit forecast.
Researchers using a stripped-down experimental system have exposed the possible function, in the healthy brain, of a mysterious molecule that has been strongly implicated in Parkinson's disease, a degenerative disorder of the central nervous system.
Merck & Co. will work with Pfizer Inc. to develop a new combination pill designed to treat Type 2 diabetes. The experimental pill will combine Merck's drug Januvia, Pfizer's experimental pill ertugliflozin, and metformin, an older diabetes drug.
Auxilium Pharmaceuticals Inc. announced the purchase of Actient Holdings LLC from private equity firm GTCR for $585 million. In the process Auxilium said it will get two testosterone drugs, impotence treatments, and two respiratory drugs.
A new study may help explain why women are more prone than men to a form of liver damage by implicating the hormone estrogen in the development of autoimmune hepatitis. The study reveals that estrogen and interleukin-6 collude to form a powerful duo that leads to immune cell misconduct.
Bayer has agreed to buy California-based Conceptus for around $1.1 billion to expand the kinds of birth control it offers. Conceptus makes Essure, an irreversible birth control method in which small metal and polyester coils are inserted to block a woman's fallopian tubes.
Actavis Inc. and Purdue Pharma LP are settling a patent dispute, and Actavis will be able to sell a generic abuse-resistant version of Purdue's painkiller OxyContin starting in 2014. Actavis expects more than $100 million in gross profit from generic OxyContin sales through 2015.
AbbVie Inc. topped Wall Street expectations in its first three months as a standalone company. On Jan. 1 Abbott Laboratories completed the spinoff of AbbVie, which markets the company's branded prescription drugs, including the blockbuster anti-inflammatory drug Humira.
Cognex Corp. announced the latest version of the In-Sight track & trace identification and data verification solution for healthcare serialization. This version address additional requirements for pharmaceutical and medical device manufacturers to achieve unit-level product traceability.
RainDance Technologies Inc. announced a service partner program for its growing base of research customers who are developing next-generation sequencing-based genetic testing panels to identify and characterize inherited diseases, cancers, and other human health conditions in research projects.
A range of chillers from PolyScience provide up to 1290 watts of cooling at 20°C, making them ideal for use with rotary evaporators, jacketed incubators, small reaction vessels, spectrophotometers, chromatography columns, condensers, and other devices that require robust heat removal.
A panel that advises the European Medicines Agency recommended that Avanir Pharmaceuticals' Nuedexta be approved as a treatment for pseudobulbar affect. The drug is already approved in the U.S. Being able to sell the drug in Europe would likely increase Avanir's revenues.